For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Myocardial infarction - Independent medicine & health information for consumers & professionals Myocardial infarction
Show health professional infoLatest independent information about myocardial infarction, including medicines and non-drug treatments, written and reviewed by experts in Australia.
Myocardial infarction is also known as MI, cardiac arrest or heart attack.
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
Statins remain important for people at high risk of heart attack or stroke |
NPS is urging people taking statins to continue to take their medicine as prescribed and to see their doctor if they are unsure about the benefit of the medicine for them. |
Media release | Others | 2012-03-01 19:00:00 |
Are cholesterol medicines overused? |
Medicines to treat cholesterol may be being prescribed inappropriately, according to Associate Professor Jane Smith of Bond University. Heart disease is a common problem, causing 16% of the total disease burden in Australia – second only to cancer. However treatment with statins should be focused on those at high risk |
Media release | Others | 2011-12-01 19:00:00 |
Case study 48 report: Achieving tight blood pressure control |
Patient diagnosed with hypertension after elevated readings over several months. Family history of cardiovascular disease. Despite adequate trial of lifestyle changes his BP remains elevated. |
Professional activity - Case study report | Health Professionals | 2007-07-01 00:00:00 |
Case study 51 report: Managing persistent hyperglycaemia |
Patient diagnosed with type 2 diabetes mellitus has a myocardial infarction and makes lifestyle changes. Examines optimal prescriptions when hyperglycaemia is persistent. |
Professional activity - Case study report | Health Professionals | 2008-04-01 00:00:00 |
Case study 51: Managing persistent hyperglycaemia |
Patient diagnosed with type 2 diabetes mellitus has a myocardial infarction and makes lifestyle changes. Examines optimal prescriptions when hyperglycaemia is persistent. |
Professional activity - Case study | Health Professionals | 2008-02-01 00:00:00 |
Diclofenac and cardiovascular risk |
Fact sheet reviewing the evidence for vascular risk associated diclofenac and other NSAIDs. |
Media factsheet | Health Professionals,Others | 2006-09-15 00:00:00 |
Diclofenac and cardiovascular risk |
Fact sheet reviewing the evidence for vascular risk associated diclofenac and other NSAIDs. |
Professional publication - NPS factsheet | Health Professionals | 2006-09-15 00:00:00 |
Eplerenone (Inspra) for use after acute myocardial infarction complicated by heart failure |
Reviews use of eplerenone for heart failure after acute myocardial infarction. Discusses the risk of hyperkalaemia and sex-hormone-related adverse effects. |
Professional publication - NPS RADAR - Review | Health Professionals | 2006-04-01 00:00:00 |
Indicators of Quality Prescribing: 13 |
Indicators of Quality Prescribing: Indicator 13 Myocardial Infarction. This indicator asks practices what percentage of patients with a history of myocardial infarction (MI) have not been prescribed a beta blocker, antiplatelet agent (or anticoagulant) and statin. |
Professional tool - Indicators of quality prescribing | Health Professionals | 2006-02-01 00:00:00 |
Keep taking your statins: benefits outweigh risks |
Recent media reports suggest statin medicines increase the risk of diabetes & memory loss in patients. However, research shows that the benefits of statins outweigh the risks & NPS is advising people to keep taking their statin medicines, unless their doctor says otherwise. Read more on the risks & benefits of statins here |
Web page | Consumers | 2012-03-01 00:00:00 |
New information on Varenicline (Champix) inconclusive: NPS (for consumers) |
New research linking an anti-smoking medicine to an increased risk of heart attacks remains uncertain. Anyone with concerns about taking the medicine should talk to their health professional or seek more information, according to NPS MedicineWise |
Media release | Others | 2011-07-20 19:00:00 |
New information on Varenicline (Champix) inconclusive: NPS (health professionals) |
Uncertainty remains despite new research published this month linking a smoking-cessation medicine to an increased risk of heart attacks, according to NPS |
Media release | Others | 2011-07-20 19:00:00 |
Ischaemic heart disease |
Examines use of multiple medications for patients with ischaemic heart disease, focusing on aspirin use, symptom control with nitrates and GP support. |
Professional publication - NPS News | Health Professionals | 2005-08-01 00:00:00 |
NPS Prescribing Practice Review 31: Ischaemic heart disease |
Information on the multiple medications that are often necessary in the treatment of ischaemic heart disease including aspirin, statins, beta blockers and ACE inhibitors. |
Professional publication - Prescribing Practice Review | Health Professionals | 2005-09-01 00:00:00 |
NPS Prescribing Practice Review 31: Ischaemic heart disease |
Information on the multiple medications that are often necessary in the treatment of ischaemic heart disease including aspirin, statins, beta blockers and ACE inhibitors. |
Professional publication - Prescribing Practice Review | Health Professionals | 2005-09-01 00:00:00 |
Rosiglitazone and cardiovascular risk |
Fact sheet on a meta-analysis of clinical trials which reported that rosiglitazone is responsible for a small increase in the risk of myocardial infarction. |
Professional publication - NPS factsheet | Health Professionals | 2007-07-25 00:00:00 |
Switching patients from Vioxx |
Fact sheet providing general advice about switching patients from rofecoxib (Vioxx) after its withdrawal due to an increased risk of cardiovascular events associated with use. |
Professional publication - NPS factsheet | Health Professionals | 2004-10-07 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
